Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Neoplasms 1Endometrial Neoplasms 1Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 271Specimen Handling 266pembrolizumab 233Cyclophosphamide 219Radiotherapy 208Nivolumab 169Cisplatin 165Biopsy 152Carboplatin 145Radiosurgery 131fludarabine 125Blood Specimen Collection 120Gemcitabine 113Paclitaxel 109Surveys and Questionnaires 108Standard of Care 106venetoclax 97Dexamethasone 95Bevacizumab 93Radiation 87Rituximab 83Capecitabine 81Cytarabine 80Oxaliplatin 77Drug Therapy 76Doxorubicin 75Ipilimumab 74durvalumab 73fludarabine phosphate 70atezolizumab 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × VMBP protocol × 90 days × Clear all
NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting
37 enrolled
Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡